Lexicon Pharmaceuticals | LXRX - Operating Profit

Stock Price
1.31
Daily Change
0 0%
Monthly
5.65%
Yearly
66.90%
Q1 Forecast
2.01

Lexicon Pharmaceuticals reported $-55.35M in Operating Profit for its fiscal quarter ending in June of 2024.





Operating Profit Change Date
Abbott USD 2.25B 73M Dec/2025
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
Agios Pharmaceuticals USD -121.58M 4.71M Dec/2025
Akebia Therapeutics USD 13.51M 27.82M Mar/2025
Alnylam Pharmaceuticals USD 29.4M 59.36M Dec/2025
AstraZeneca USD 2.97B 4.48B Dec/2025
BioMarin Pharmaceutical USD -31.69M 308.58M Sep/2025
Coherus Biosciences USD -45.43M 3.13M Mar/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
Halozyme Therapeutics USD 217.92M 15.48M Sep/2025
Illumina USD 256M 6M Dec/2025
Insmed USD -261.35M 7.48M Sep/2025
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
J&J USD 5.59B 1.81B Dec/2025
Lexicon Pharmaceuticals USD -55.35M 10.02M Jun/2024
MacroGenics USD 18.64M 55.4M Sep/2025
MannKind USD -41.05M 2.36M Sep/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -857M 597M Dec/2025
Novartis USD 4.5B 363M Sep/2025
PTC Therapeutics USD 3.49M 38.35M Sep/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Thermo Fisher Scientific USD 2.3B 226M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
United Therapeutics USD 389.3M 112.4M Sep/2025
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024